Skip to Main content Skip to Navigation

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Abstract : Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-tours.archives-ouvertes.fr/hal-02425330
Contributor : Valérie Gouilleux <>
Submitted on : Monday, December 30, 2019 - 12:18:22 PM
Last modification on : Friday, January 10, 2020 - 4:12:21 PM

Links full text

Identifiers

Collections

Citation

Bertrand Lioger, Soujanya Ratna Edupuganti, Denis Mulleman, Christophe Passot, Celine Desvignes, et al.. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. British Journal of Clinical Pharmacology, Wiley, 2017, 83 (8), pp.1773-1781. ⟨10.1111/bcp.13270⟩. ⟨hal-02425330⟩

Share

Metrics

Record views

46